Search Results - "Mora‐Peris, B"

  • Showing 1 - 12 results of 12
Refine Results
  1. 1

    Pharmacokinetic profile of maraviroc 150 mg dosed with darunavir/ritonavir once daily, with and without nucleoside analogues, in HIV‐infected subjects by MoraPeris, B, Croucher, A, Else, L, Khoo, S, Vera, J, Back, D, Winston, A

    Published in Journal of the International AIDS Society (01-11-2012)
    “…Background Once‐daily nucleoside‐sparing combination antiretroviral therapy (cART) regimens, such as maraviroc/darunavir/ritonavir, may be attractive…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Raltegravir resistance in the cerebrospinal fluid by Mora-Peris, B., Mackie, N. E., Suan, D., Cooper, D. A., Brew, B. J., Winston, A.

    Published in Infection (01-06-2013)
    “…We report the first published case of integrase inhibitor resistance in the central nervous system compartment in the absence of evidence of integrase…”
    Get full text
    Journal Article
  4. 4

    In vitro activity of newer antibiotics against Corynebacterium jeikeium, Corynebacterium amycolatum and Corynebacterium urealyticum by SANCHEZ HERNANDEZ, J, MORA PERIS, B, YAGÜE GUIRAO, G, GUTIERREZ ZUFIAURRE, N, MUNOZ BELLIDO, J. L, SEGOVIA HERNANDEZ, M, GARCIA RODRIGUEZ, J. A

    “…The in vitro activity of ciprofloxacin, erythromycin, telithromycin, teicoplanin, linezolid and quinupristin-dalfopristin was tested against human derived…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy by Mora-Peris, Borja, Watson, Victoria, Vera, Jaime H., Weston, Rosy, Waldman, Adam D., Kaye, Steve, Khoo, Saye, Mackie, Nicola E., Back, David, Winston, Alan

    Published in Journal of antimicrobial chemotherapy (01-06-2014)
    “…Objectives Pharmacokinetic parameters following modifications to antiretroviral therapy and sanctuary site exposure are often unknown for recently licensed…”
    Get full text
    Journal Article
  7. 7

    Implicación de los genes "ermX" en la resistencia a los macrólidos y la telitromicina de "Corynebacterium jeikeium" y "Corynebacterium amycolatum" by Segovia Hernández, M, Valero Guillén, P.L, Martínez Toldos, M.C, Rodríguez González, T, Yagüe Guirao, G, Mora Peris, B

    Published in Revista española de quimioterapia (01-09-2005)
    “…Se ha estudiado la actividad de siete macrólidos, clindamicina y telitromicina frente a aislamientos clínicos del género Corynebacterium. De éstos, 36…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10

    Implication of ermX genes in macrolide- and telithromycin-resistance in Corynebacterium jeikeium and Corynebacterium amycolatum by Yagüe Guirao, G, Mora Peris, B, Martínez-Toldos, M C, Rodríguez González, T, Valero Guillén, P L, Segovia Hernández, M

    Published in Revista española de quimioterapia (01-09-2005)
    “…The activity of seven macrolides, clindamycin and telithromycin against clinical isolates of Corynebacterium spp. was studied. Of these, 36 isolates were…”
    Get full text
    Journal Article
  11. 11

    Hemorrhagic cystitis caused by BK and JC polyomavirus in patients treated with bone marrow transplantation: clinical features and urologic management by García Ligero, J, Mora Peris, B, García García, F, Navas Pastor, J, Tomás Ros, M, Sempere Gutiérrez, A, Rico Galiano, J L, Fontana Compiano, L O

    Published in Actas urologicas españolas (01-02-2002)
    “…Differential diagnosis of hematuria after bone marrow transplantation (B.M.T.) may include polyomavirus (BK and JC)-associated haemorrhagic cystitis. Many…”
    Get more information
    Journal Article
  12. 12

    Activity of new quinolones against clinical isolates of Corynebacterium species by Yagüe Guirao, G, Martínez-Toldos, M C, Mora Peris, B, López Domínguez, R, Romero Otero, M, Muñoz Bellido, J L, Segovia Hernández, M

    Published in Revista española de quimioterapia (01-09-2000)
    “…The activity of six quinolones (ciprofloxacin, levofloxacin, trovafloxacin, moxifloxacin, clinafloxacin and grepafloxacin) against 86 clinical isolates of…”
    Get full text
    Journal Article